Pathogenesis of Pseudophakic Cystoid Macular Oedema

Conceição Lobo

Ophthalmologist, Department of Ophthalmology, University Hospital of Coimbra; Principal Investigator, Association for Innovation and Biomedical Research on Light and Image (AIBIL) and Institute of Biomedical Research on Light and Image (IBIL), and invited Professor of Ophthalmology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

Abstract
Cystoid macular oedema (CMO) is a primary cause of reduced vision after cataract surgery even after uneventful surgery. The incidence of clinical CMO following modern cataract surgery is 1.0–2.0 % but the high number of surgeries performed worldwide makes this entity an important problem. Pre-existing conditions such as diabetes and intra-operative complications increase the risk of developing CMO post-operatively. CMO is caused by an accumulation of intra-retinal fluid in the outer plexiform and inner nuclear layers of the retina, as a result of the breakdown of the blood–retinal barrier. The mechanisms that lead to this condition are not completely understood. However, the principal hypothesis is that the surgical procedure is responsible for the release of inflammatory mediators, such as prostaglandins. Optical coherence tomography is at present an extremely useful non-invasive diagnostic tool. Guidelines for the management CMO should be focused essentially on prevention and are based on the principal pathogenetic mechanisms, including the use of anti-inflammatory drugs.

Keywords
Cataract surgery, cystoid macular oedema, pathogenesis, inflammatory mediators, anti-inflammatory drugs, management

Disclosure: The author has no conflict of interest to declare.
Received: 7 October 2011 Accepted: 18 November 2011 Citation: European Ophthalmic Review, 2012;6(2):290-4. DOI: 10.17925/EOR.2012.06.05.290
Correspondence: Conceição Lobo, Association for Innovation and Biomedical Research on Light and Image, Avinhão de Santa Comba, Celas, 3000-548 Coimbra, Portugal, E: dobofonseca@gmail.com

Modern cataract extraction using phacoemulsification and posterior intraocular lens (IOL) implantation is one surgical procedure considered extremely safe and successful.\(^1\)\(^-\)\(^2\) The constant innovations in instrumentation, lens design and surgical technique lead to improved outcomes following this surgery.\(^3\)\(^-\)\(^4\) Although the procedure is efficient, and uneventful surgery is generally associated with good visual results,\(^5\)\(^-\)\(^6\) complications, such as cystoid macular oedema (CMO) may develop, and this can result in sub-optimal post-operative vision.\(^7\)\(^-\)\(^8\) It can occur after uncomplicated surgery in patients with otherwise healthy eyes, after complicated surgery, or after surgery in patients with ocular diseases such as uveitis or diabetic retinopathy.\(^9\)

CMO following cataract surgery was an entity reported first time by Irvine in 1953. Thirteen years later, Gass and Norton demonstrated its typical presentation using fluorescein angiography (FA); therefore, it is known as Irvine–Gass syndrome.\(^10\)\(^-\)\(^12\)

The pathogenesis of CMO following cataract surgery remains uncertain, but clinical observations and experimental studies indicate that the pathophysiology of this post-operative problem may be multifactorial.\(^13\)\(^-\)\(^14\) Prostaglandin-mediated inflammation\(^15\)\(^-\)\(^16\) and the subsequent breakdown of the blood–aqueous humour (BA) and blood–retinal barrier (BRB) are probably the more important facts involved.\(^17\)\(^-\)\(^18\)

Clinical CMO is diagnosed in those patients who have detectable visual impairment as well as angiographic and/or biomicroscopic findings. Some patients who are asymptomatic with respect to visual acuity, but have detectable leakage from the perifoveal capillaries on FA, are diagnosed as angiographic CMO. Optical coherence tomography (OCT) confirms the clinical diagnosis. So, the incidence of pseudophakic CMO depends not only on the surgical technique or pre-existing conditions, but also on the methodology used in its detection.

The actual guidelines recommend the use of non-steroidal anti-inflammatory drugs (NSAIDs) pre-operatively, and the combination of steroids and NSAIDs in the post-operative period, to reduce the incidence of pseudophakic CMO.

Risk Factors
The principal risk factors associated to pseudophakic macular oedema are the type of cataract surgery; complications during the surgery, such as vitreous loss, rupture of the posterior capsule, iris incarceration or retained lens fragments; and some pre-existing conditions, such as uveitis or diabetes.\(^19\)\(^-\)\(^24\)

Type of Cataract Surgery
The choice of cataract surgery procedure is associated with different outcomes and complications, such as CMO. The change in procedure from large-incision intracapsular cataract extraction and extracapsular to small-incision phacoemulsification was associated with a clear decrease in the incidence of this complication.\(^19\)\(^-\)\(^24\) This has been explained by less BA barrier damage after phacoemulsification with an intact continuous curvilinear capsulorhexis than after extracapsular cataract extraction (ECCE).\(^25\)\(^-\)\(^27\)
Specific IOLs implanted are associated with increased occurrence of CMO: anterior chamber IOLs, specifically iris-fixed, raise the risk more than posterior chamber IOLs.13,34

**Surgical Complications**

Although CMO can occur after uneventful cataract surgery, certain surgical complications raise the risk of CMO. Rupture of the posterior capsule and vitreous loss are associated with a higher rate of CMO.7,13,34-36 Different studies have confirmed that the rate of clinical CMO associated with vitreous loss is higher compared with cases without this complication.36-38 The lower rate of CMO occurring when there is vitreous loss during phacoemulsification compared with extracapsular extraction has also been explained by the small wound construction and greater stability in this type of surgery compared with large-incision cataract surgery.39,40 Vitreous to the wound prolongs CMO, and can be associated with a worse prognosis.39 Iris incarceration, considered an additional risk factor for CMO, may have a more important association with poor vision in patients with chronic post-surgical CMO than with other intra-operative complications.41,42 Retained lens fragments, even when they are removed by pars plana vitrectomy, is another complication associated with an increased rate of CMO and more severe visual loss, in eyes with a suture fixed posterior chamber IOL, anterior chamber IOL or aphakic eyes.43,44 Retained lens fragments cause inflammation that is often severe, and these eyes additionally have longer cataract surgery times than eyes with uneventful cataract extraction.

**Pre-existing Conditions**

In diabetic patients, especially those with pre-existing diabetic retinopathy, there is an increased risk of CMO.10 The incidence of CMO in diabetic patients, even in the absence of diabetic retinopathy, is higher than in patients without this pathology.10 Although the frequency of this problem has decreased with the widespread use of smaller incisions and phacoemulsification, it remains an important issue to consider.10 The poor visual acuity after cataract surgery in these patients due to macular oedema is common, and the two clinical forms (diabetic macular oedema and oedema caused by Irvine-Gass syndrome) probably co-exist and may facilitate the occurrence.23,51 These are difficult to differentiate, although some authors have suggested that if there is post-operative hyperfluorescence of the optic disc in the angiograms, it probably corresponds to a CMO that would be likely to resolve spontaneously.20 It is very important to take into consideration that if the patient has already some degree of macular oedema when the cataract surgery is considered, it should be treated before the surgery. In cases when this is not possible it is proposed to use intravitreal anti-inflammatory medication at the time of surgery.

Patients with uveitis frequently develop CMO, and it is the most common reason for poor outcomes of cataract surgery in these patients.13 It is important to note that there is a wide variation in severity of uveitis, and surgeons should consider these patients at risk of post-operative CMO.45-46 Taking this into account, it is imperative to control pre-operative inflammation and introduce post-operative medication according the expected risk.

In conclusion, the most frequent risk factors associated with pseudophakic CMO are iris trauma, rupture of the posterior capsule, vitreous loss or incarceration, dislocated IOL, use of iris-fixed lenses, active uveitis and diabetes.

**Figure 1: Arachidonic Acid Cascade and Mechanism of Action of Anti-inflammatory Drugs**

- **Lipoxygenase**
- **Phospholipase A₂**
- **Cyclooxygenase**
- **Prostaglandin (PGE₂, PGF₂, PGD₂)**
- **Cortisone**
- **NSAIDs**
- **Prostacyclin (PGL₃)**

NSAIDs = non-steroidal anti-inflammatory drugs.

**Pathogenesis**

Clinical observations and experimental studies indicate that the pathophysiology of CMO following cataract surgery is multifactorial.33,34 Many pathophysiological mechanisms for CMO after cataract surgery have been proposed, but the most compelling at the present time is that surgery causes anterior segment inflammation, which results in the release of endogenous inflammatory mediators, including prostaglandins.7,13,20,34

**Inflammation**

The term inflammation is used in this context as the inflammatory repair response to the surgical procedure with production of a variety of eicosanoids. Eicosanoids are defined as prostaglandins, leukotrienes and other compounds that are products of the action of phospholipase A₂ on the cellular phospholipid membrane and are, in general, derived from the production of arachidonic acid (see Figure 1).13,33 The cyclooxygenase enzymes (COX) play a role in the arachidonic acid cascade to produce the different eicosanoids. These enzymes are important in maintaining cellular integrity and preventing apoptosis in eukaryotes,46 with the eicosanoid products of COX playing important roles in cellular homeostasis, such as modulation of platelet function.46 Nevertheless, as a response to injury there is an upregulation of the COX enzyme system, resulting in overproduction of eicosanoids required for cellular homeostasis.

**Iris Trauma**

During the cataract surgery, associated with surgical manipulation, a variable degree of trauma to the iris may occur. It is known that the iris is a metabolically active tissue that releases inflammatory mediators when traumatised. After surgery, the physiological healing process is sufficient to slowly, but progressively, suppress the inflammation.36 In about 90 % of patients with macular oedema following cataract surgery, a spontaneous resolution of the oedema and a recovery of visual acuity can be observed. In specific situations, excessive leakage occurs, which can lead to severe and irreversible impairment of visual acuity. The different degrees of leakage explain the higher incidence of angiographically detectable CMO compared with clinically identified CMO.51

**Lens Epithelial Cells**

Additionally, there are different studies that have shown that lens epithelial cells when traumatised by surgery also synthesise inflammatory mediators, including prostaglandins.7,13,20,34 The receptors for prostaglandins are located widely in the eye, but especially in the
Anterior Segment  Cystoid Macular Oedema

ciliary body and iris sphincter. Increased levels of prostaglandins in the eye have been demonstrated after cataract surgery and they are considered one of the major mediators of inflammation and vascular permeability. The common feature of many of the risk factors that are thought to contribute to development of CMO is, therefore, chronic ocular inflammation with associated BAB breakdown.

Mediators of inflammation

It has been postulated that, after cataract surgery, inflammation mediators (prostaglandins, cytokines and other vascular permeability factors) are released from the anterior segment of the eye and diffuse to the vitreous cavity and retina, stimulating the breakdown of the BRB and subsequent leakage of fluids across the retinal vessel wall and through the retinal pigment epithelium (RPE) into perifoveal retinal tissues, resulting in macular oedema.

Different studies support the idea that the arachidonic acid cascade is not the only chemical mediator related to post-operative inflammation. It is believed that other substances are also involved, such as complement, platelet-activating factor (PAF), lysisomenzym, cytokines, nitric monoxide and endothelin. One cytokine well studied is interleukin-6 (IL-6). An increased level of this mediator was found in the aqueous humour of patients undergoing cataract surgery.

The cytokines produce COX-2, and PAF interacting with interleukins and prostaglandins is believed to be responsible for inflammatory reactions. Additionally, other studies reported that endothelin was an inducer of the arachidonic cascade but that inhibitors of COX prevent the inflammation of the anterior chamber induced by endothelin.

Cyclooxygenases

Developing knowledge concerning COX is leading to a better understanding of the different pathways involved. Some studies confirmed that there are two types of COX. COX-1, a constitutive isomier, is responsible for the biosynthesis of prostaglandins associated with the homeostasis of normal tissue and is present in all tissues. COX-2, the induced isomier, biosynthesises prostaglandins associated with inflammation and appears in response to stimulation from proiferative factors, such as IL-1ß or endotoxin. Based on these different mediators the management of CMO post cataract surgery is centred on the development of drugs to block these mediators and if possible with minor side effects. NSAIDs are non-selective, as they inhibit both COX-1 and COX-2, whereas steroid drugs interfere with the activity of phospholipase A2, selectively inhibiting COX-2 (see Figure 1).

Vitreous Traction

Although the most widely accepted explanation for the aetiology of CMO after cataract surgery is inflammation in the anterior segment associated with disruption of the BAB, releasing mediators, particularly prostaglandins, that diffuse posteriorly leading to breakdown in RRS and consequent macular oedema, other theories have been proposed. One of potential clinical importance is that tractional forces on the foveal area exerted by the vitreous lead to CMO. Since the vitreous inserts into the internal limiting membrane, which is attached to the Müller fibres, these cells could be particularly affected by vitreous traction, leading to macular oedema. The minimal traction on the vitreomacular interface in the phacoemulsification procedure compared with ECCE is also the explanation for the reduced risk of CMO in these patients.

Summarising, inflammatory mediators probably play the essential initiating role in the development of inflammatory CMO, but other factors and events responsible for further CMO development and its chronicity have not yet been clearly identified.

Incidence

The improvement in the procedures associated with cataract surgery, such as decreasing surgical incision, progressively smaller microsurgical instrumentation and minimal turbulence during the surgery, are responsible for the progressive decline in the rate of occurrence of CMO. Despite of this, the high volume of cataract surgeries performed each year still makes CMO a common cause of poor vision in pseudophakic patients.

There are multiple reports comparing the incidence of clinical and angiographic CMO under specific anti-inflammatory drugs. These reports and reviews on this subject show different numbers and the explanations are, in certain cases, unclear. The use of different prophylactic medications before and after cataract surgery and variations in the patient populations evaluated, with varying risk factors, contribute to the difficulty in determining the overall real incidence of CMO. Another factor that contributes to this variability is the use of different methods to evaluate macular thickness. However, it is important to recognise the many variables involved and the difficulty in identifying their potential impact on the interpretation of results from therapeutic trials that evaluated potential treatments for CMO.

The true current incidence of clinical CMO using modern surgical techniques, such as small-incision phacoemulsification with implantation of a foldable IOL, especially if it occurs without complications, appears to be very low. It is likely to be in the range of 0.2–2 %, although the rate of angiographic CMO is at least 10-fold higher. These numbers increase if another surgical technique is required, such as large incision and different IOL implantation or, if we have a complicated surgery with iris trauma, capsule rupture with vitreous loss, or in patients at high risk, such as those with uveitis or diabetes.

Diagnosis

Signs and symptoms of clinically significant CMO typically develop four to 12 weeks after surgery and reach a peak at four to six weeks post-operatively. The patient may complain of impaired vision after an initial period of improved vision due to the cataract removal.

The diagnosis of CMO can generally be made on clinical examination with evidence of perifoveal cystic spaces, and has traditionally been confirmed with use of FA to document the classic petaloid pattern of leakage induced by inflammatory mediators that leads to breakdown of the BRB. Today, the most objective evidence is obtained from non-invasive OCT examination.

Usually, CMO has a good response with only topical anti-inflammatory medications. However, some cases respond poorly to this conservative treatment and can persist for more than six months, developing permanent visual loss. Although the incidence of chronic CMO is much less frequent, being reported at 1–2 % of uncomplicated cases and about 8 % after complicated cataract surgery, the associated vision loss makes it an important complication.

The diagnosis of clinical CMO is considered in those patients who have detectable visual impairment as well as angiographic and/or biomicroscopic findings. In patients with detectable leakage from perifoveal capillaries on FA but otherwise asymptomatic with respect
to visual acuity, the diagnosis of angiographic CMO can be considered. An even higher incidence of alterations in the period immediately after cataract surgery can be shown with vitreous fluorometry, a more sensitive technique for measuring alterations in the RBB using fluorescein.22 The retinal leakage analyser is another methodology that can be used to objectively measure the disruption of the RBB, leading to a quantitative evaluation of the macular oedema.24

With OCT, it is possible to observe the cystic spaces in the outer nuclear layer of the central macula and measure the oedema, which should correspond to the value of the observed retinal thickening.25-27 Foveal thickness can increase significantly and, although the correlation with the decrease in visual acuity is only moderate, it is clearly better than the correlation between FA and visual acuity.

Although FA has been considered indispensable for the diagnosis of pseudophakic CMO, OCT is now the method of choice due to the fact that it is a non-invasive technique that leads to a precise evaluation of CMO in order to follow each case after cataract surgery.28 An additional advantage of the use of OCT is that the thickening of the macular area effectively measures the oedema, and therefore correlates better with vision than the possible grade performed with FA.29

Management
Angiographic CMO is not necessarily associated with poor visual outcome. Most cases of post-operative CMO resolve spontaneously, with only about 1–3% of cases persisting, and this corresponds to clinical CMO with persistent symptoms.30-32 Nevertheless, it is now widely accepted that in cataract surgery it is important to perform therapeutic intervention using anti-inflammatory drugs in cases diagnosed as clinical CMO to treat, but also and specifically in all cases, to prevent the development of CMO after cataract surgery.

The available therapeutic approaches for the prophylaxis and treatment of CMO, such as topical steroids and NSAIDs, are based on theories regarding the pathogenesis of the condition;4-6-8 therefore, it is directed towards blocking the inflammatory mediators, mainly the prostaglandins in the anterior segment of the eye. Clinical evidence suggests that the combined use of steroids and NSAIDs is synergetic.6-8-9-10 This synergetic effect is based on the different mechanism of action of the two drugs.10-11

Corticosteroids and NSAIDs
Corticosteroids are effective, and are considered the gold standard for the treatment of ocular inflammation, but they are associated with an increased incidence of adverse events, including a rise in intraocular pressure (IOP) in a small percentage of patients.12-14 Due to this limitation the cataract surgeons are interested in alternative treatments with similar effectiveness but with fewer complications. These are the NSAIDs and they vary in their relative potency against COX-1 and COX-2 in the post-cataract surgery setting. COX-2-specific activity is important because it is the form of the enzyme that is believed to be the primary mediator of ocular inflammation.

Multiple studies have been performed to test the efficacy of the different available NSAIDs in the prevention and treatment of pseudophakic CMO.9-11,14-15,16 However, these studies usually have been poorly designed and, although in general they have proven the effectiveness of use of this type of medication in preventing both angiographic and clinical CMO,26 the absence of clear statistical differences between the different NSAIDs is the reason controversy persists over which to use.

Topical NSAIDs are classified into different groups based on their chemical composition. There is some difficulty in obtaining an ideal formulation of NSAIDs to be applied topically to the eye.33 Some are considered too toxic to be used in the eye; others are weakly acid thus they have a limited permeability through the cornea and, on the other hand, the acid drugs are a potential irritant. There are, however, at the moment, several NSAIDs approved in EU for treatment of post-operative inflammation after cataract surgery: ketorolac, dicyfenac, flurbiprofen, indometacin, nepafenac and bromfenac.34

The two more recently introduced drugs in the European market—napafenac and bromfenac—have some potential advantages, due to rapid penetration in ocular tissues related to high corneal permeability.35,36,37 They have been developed to exploit the anti-inflammatory potency of amfenac within the eye. Amfenac is a highly potent inhibitor of both COX-1 and COX-2, but it is unable to penetrate the corneal epithelium.38 Nepafenac is an inactive precursor of amfenac that can penetrate the corneal epithelium and within the eye must then be converted to the active amfenac. Bromfenac is structurally identical to amfenac but with some specific differences that make it a highly lipophilic molecule, which facilitates its rapid penetration through the cell membrane of various tissues, including ocular, to obtain sustained drug levels, increasing the duration of analgesic and anti-inflammatory activity.39-41

Another point of discussion is related to the timing of the use of steroids and NSAIDs before surgery.42,43 It is now considered essential to use NSAIDs and/or steroids, in risk cases, before surgery during a variable period according to each specific situation. In other cases the use of NSAIDs should be considered at least two days before surgery.44-45

Current Guidelines
The current guidelines for managing post-cataract surgery inflammation are based on the premise that the prevention of inflammation should be the main goal. So, it is mandatory to perform good patient selection and correct eye/patient preparation according the possible risk factors. During surgery it is very important to take special care not to cause iris trauma. Additionally, if there are any intra-operative complications the appropriate resolution is recommended and any case of post-operative inflammation should be timely treated.46

In the presence of a normal patient, it is recommended as prophylaxis to administer topical NSAIDs during the first month in combination with topical steroids during the first two weeks in decreasing doses. In patients with evidence of anterior segment inflammation or if there is recognised CMO, the topical NSAIDs and steroids should be reintroduced for another month. After this, visual acuity should be evaluated and an OCT should be performed to estimate any possible improvement in the CMO. If the CMO has not improved, the introduction of acetazolamide (for one month or more) should be considered or, as an alternative, a local sub-conjunctival injection of corticosteroid. High-dose intravitreal administration of corticosteroid, such as triamcinolone, should be reserved for severe refractory cases. This can reduce macular oedema and improve vision in eyes with CMO that persists or recurs despite previous medical treatment.47-48 However, CMO may recur in some cases, even after more than one intravitreal injection of triamcinolone acetonide.

®
Anterior Segment  Cystoid Macular Oedema

Carbonic Anhydrase Inhibitors

The rationale for the use of carbonic anhydrase inhibitor – acetazolamide – is based on its effect in helping to reduce the oedematous component by stimulating the RPE to pump excess fluid out of the macula. Carbonic anhydrase inhibitors induce acidification of the sub-retinal space, and thereby increase fluid resorption from the retina through the RPE into the choroid.101,102 There are some reports documenting the efficacy of acetazolamide on post-surgical CMO.103-105

Anti-angiogenic Agents

The use of anti-angiogenic agents has also been proposed as an alternative therapeutic approach in some cases of refractory CMO. Vascular endothelial growth factor (VEGF) is a potent inducer of alterations in the BRB and, being a crucial mediator in post-operative CMO, may be increased in post-operative CMO. The anti-VEGF agents reduce vascular permeability by a mechanism of action distinct from prostaglandin inhibition.105,106 However, bevacizumab, a monoclonal antibody against all isoforms of VEGF that has been used to treat some neovascular eye diseases, was used in patients with post-operative CMO without improvement concerning visual acuity.107

Laser and Surgical Treatment

Vitreous incarceration in the cataract incision wound is associated with increased incidence of CMO after cataract surgery. Vitrectomy using the Nd:YAG laser has shown promising results for such cases.108

In some specific conditions, such as vitreous incarceration with persistent inflammatory reaction or in chronic CMO, surgical treatment, namely vitrectomy, is indicated and it is associated with visual acuity improvement.109,110 The rationale for performing vitrectomy in CMO following surgery includes the removal of vitreous adhesions and inflammatory mediators and improved access of topical medication to the posterior pole.111

Diabetic Patients

Diabetic patients, specifically if they have pre-surgical macular oedema, are considered a higher risk group and the possibility of worsening their macular oedema after cataract surgery is considered. Based on this possibility it is recommended to first treat the macular oedema and perform the surgery only when the situation is assumed stable. In these cases, the use of intravitreal triamcinolone acetone (4 mg) injected at the end of cataract surgery should be recommended.112

Conclusion

Phacoemulsification using small incision and implantation of a foldable intraocular lens (IOL) is one of the most commonly performed surgeries. The procedure is efficient, and uneventful surgery is generally associated with good visual results. Nevertheless, CMO may develop and can result in sub-optimal post-operative vision. The incidence of clinical CMO following modern cataract surgery is 1.0–2.0 % but the high number of surgeries performed worldwide makes this entity an important problem.

The most widely accepted explanation for the pathophysiology of CMO after cataract surgery is inflammation in the anterior segment associated with disruption of the BAB, releasing mediators, particularly prostaglandins, that diffuse posteriorly leading to breakdown of the BRB and consequent macular oedema.

Although FA has been considered indispensable for the diagnosis of pseudophakic CMO, OCT is now the method of choice due to the fact that it is a non-invasive technique. Another advantage of OCT is that it measures the thickening of macular area, and this is a parameter that correlates better with vision than the possible function performed with FA.

The current guidelines for managing post-cataract surgery inflammation are based on the premise that the prevention of inflammation should be the main goal. It is mandatory to perform good patient selection and correct eye/patient preparation according to the possible risk factors. Although the treatment options depend on the underlying cause of CMO, the usual therapeutic approach for prophylaxis and treatment of CMO is directed towards blocking the inflammatory mediators, mainly the prostaglandins in the anterior segment of the eye, using topical steroids and NSAIDs.
